English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Ranolazine is a recently developed drug used for the treatment of patients with chronic stable angina. It is a selective inhibitor of the persistent cardiac Na +  current (I Na ), and is known to reduce the Na + -dependent Ca 2+  overload that occurs in cardiomyocytes during ischemia. Vascular effects of ranolazine, such as vasorelaxation,have been reported and may involve multiple pathways. As voltage-gated Na +  channels (Na v ) present in arteries play a role in contraction, we hypothesized that ranolazine could target these channels. We studied the effects of ranolazine  in vitro  on cultured aortic smooth muscle cells (SMC) and  ex vivo  on rat aortas in conditions known to specifically activate or promote I Na . We observed that in the presence of the Na v  channel agonist veratridine, ranolazine inhibited I Na  and intracellular Ca 2+  calcium increase in SMC, and arterial vasoconstriction. In arterial SMC, ranolazine inhibited the activity of tetrodotoxin-sensitive voltage-gated Na v  channels and thus antagonized contraction promoted by low KCl depolarization. Furthermore, the vasorelaxant effects of ranolazine, also observed in human arteries and independent of the endothelium, involved antagonization of the α 1 -adrenergic receptor. Combined α 1 -adrenergic antagonization and inhibition of SMCs Na v  channels could be involved in the vascular effects of ranolazine.

Antagonism of Nav channels and α1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine